The drug maker has acquired closing approval from the US drug regulator for its Abbreviated New Drug Software (ANDA) doxepin hydrochloride capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg.
The authorized ANDA is therapeutically equal to the reference listed drug product (RLD), Sinequan capsules of Pfizer Inc. The drug is is used to deal with psychological/temper issues corresponding to melancholy and anxiousness.
The capsules have an estimated market measurement of $41 million for twelve months ending December 2020 in line with IQVIA.
Alembic has a cumulative complete of 141 ANDA approvals (124 closing approvals and 17 tentative approvals) from USFDA.
Alembic Prescription drugs is a vertically built-in analysis and improvement pharmaceutical firm. It manufactures and markets generic pharmaceutical merchandise everywhere in the world.
The drug maker reported 13.8% bounce in consolidated internet revenue to Rs 259.20 crore on a 8.7% rise in internet gross sales to Rs 1,314.33 crore in Q3 FY21 over Q3 FY20.
The Alembic Pharma scrip was up 0.29% to Rs 1006.65 on the BSE.
Powered by Capital Market – Stay Information
(This story has not been edited by Enterprise Normal workers and is auto-generated from a syndicated feed.)
Enterprise Normal has at all times strived onerous to supply up-to-date info and commentary on developments which are of curiosity to you and have wider political and financial implications for the nation and the world. Your encouragement and fixed suggestions on how one can enhance our providing have solely made our resolve and dedication to those beliefs stronger. Even throughout these tough instances arising out of Covid-19, we proceed to stay dedicated to retaining you knowledgeable and up to date with credible information, authoritative views and incisive commentary on topical problems with relevance.
We, nonetheless, have a request.
As we battle the financial impression of the pandemic, we’d like your help much more, in order that we are able to proceed to give you extra high quality content material. Our subscription mannequin has seen an encouraging response from a lot of you, who’ve subscribed to our on-line content material. Extra subscription to our on-line content material can solely assist us obtain the objectives of providing you even higher and extra related content material. We imagine in free, honest and credible journalism. Your help by extra subscriptions may also help us practise the journalism to which we’re dedicated.
Assist high quality journalism and subscribe to Business Standard.